BLR Bio LLC, in collaboration with Dr. Andrew Leask and his team at University of Saskatchewan received an International Research Partnership Fund grant from the University of Saskatchewan titled “BLR-200 :A novel Treatment for Fibrotic Disease”. This work will run from April 1, 2022 until August, 2024. BLR Bio will serve as the International partner supplying the drug to be evaluated as well as its expertise in animal model and drug development.
BLR Bio presents at the Festival of Biologics USA conference in San Diego, CA sharing information on the company’s cancer asset BLR-100, a CAFs (Cancer Activated Fibroblasts) targeting therapy.
BLR Bio announces pre-clinical study of the effect of BLR-200 on Interstitial Lung Disease (ILD) have been initiated to determine the therapeutic effect on markers of fibrosis in the lung.
BLR Bio announces pursuit of proteonomics analysis of its peptides in two diseases of very high medical need, Scleroderma (systemic sclerosis) and non-alcoholic steatohepatitis (NASH) disease, the latter under an NIH Phase 1 Small Business Innovative Grant . BLR is working closely with world expert collaborators from both the University of Michigan and the University of Saskatchewan. This leading-edge research will provide deep insights into both the pathways driving these disease as well as mode of action of the BLR therapeutics peptides.
BLR Bio LLC. announces results from preclinical studies demonstrating the potential role in the treatment of Pancreatic Cancer of the company’s CCN- Based Therapeutic Peptides. The studies were published in Cells 2020, 9(4), 952 titled “CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy”.
BLR Bio LLC announces initiation of work on the company’s CCN based diagnostic in an application for NASH as part of an NIH funded grant. The company is partnering with a leader in the diagnostics area based in Europe.
“Preclinical data on BLR Bio’s drug candidate BLR-200 is presented at the Victoria conference . The presentation abstract demonstrates that BLR-200 has a significant effect on the progression of key markers of injury/fibrosis in the skin in the bleomycin-induced murine model of systemic sclerosis.
“Dr. Riser presents current data on its liver injury program entitled “CCN3-based Peptide Inhibits/Reverses Liver Injury in a Mouse Model of Diabetes and Obesity” at the Keystone Symposia, Obesity and NAFLD: Mechanism and Therapeutics, in Banff, AB, Canada.